REGULATORY

MHLW Orders Label Revisions for Inlyta, Spinraza, and More

January 11, 2019
The Ministry of Health, Labor and Welfare (MHLW) on January 10 ordered adverse reaction-related label revisions to a batch of drugs including Pfizer’s cancer drug Inlyta (axitinib) and Biogen Japan’s spinal muscular atrophy (SMA) treatment Spinraza (nusinersen). The MHLW urged…

To read the full story

Related Article

REGULATORY

By Reiji Anasako

Big pharma companies are ramping up the number of female bosses in Japan, with the percentage of women in managerial posts reaching 20% or more for seven out of 10 firms that disclosed their most recent data to Jiho by…

By Yoshinori Sagehashi

As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…